Ibogaine is a psychoactive herbal medication with alleged antiaddiction properties.
| INTRODUCTION
Drug-induced QT prolongation can result in life-threatening ventricular arrhythmia and is part of the differential diagnosis of unexplained torsades de point or ventricular fibrillation. We report an uncommon case of life-threatening ventricular arrhythmia caused by massive QT prolongation after ingestion of ibogaine as antiaddiction therapy.
| CASE
A 61-year-old male presented to a holistic, naturopathic clinic for alternative treatment to overcome a long-standing opioid dependency related to chronic pain. His past medical history was significant for multiple spine operations resulting in a chronic cervicolumbar pain syndrome. Additional comorbidities included depression, mild hypertension, and dyslipidemia. He had no history of cardiovascular disease, unexplained syncope, presyncope, or sustained palpitations. His family history was negative for unexplained sudden cardiac death or inherited arrhythmia.
The patient was provided with ibogaine capsules (first-time use) that were administered with the intention to blunt opioid addiction symptoms and achieve a sustained anticraving effect. The patient ingested an approximate single dose of 5.6 g of ibogaine corresponding to a total body dose of 65-70 mg/kg. It is important to mention that ibogaine was administered without medical prescription and supervision, as this substance is not approved in North America for medical use. At 6-12 hours postingestion, the patient started to develop severe gastrointestinal symptoms including heavy vomiting and diarrhea. Those symptoms were quickly followed by a significant alteration of his level of consciousness, and the patient was urgently transferred to the ER of the nearest hospital.
On arrival at the ER, the patient was pale, diaphoretic, and barely arousable. His radial pulse was not palpable, and no blood pressure could be measured. The initial 12-lead ECG revealed a monomorphic wide QRS complex tachycardia at a rate of 270 beats per minute-representing almost ventricular flutter ( Figure 1A ). was negative.
There was no evidence of any significant heart disease after A final diagnosis of ibogaine-induced QT prolongation (cotriggered by secondary hypokalemia) triggering ventricular tachycardia was retained, and the patient was discharged home. Given his normal cardiac test results and the well-known cardiotoxicity of ibogaine, no genetic testing was performed.
| DISCUSSION
Ibogaine is a psychoactive indole alkaloid from the root bark of Tabernanthe iboga, a West-Central African rainforest shrub ( Figure S1 ). F I G U R E 2 Delayed QTc recovery after ibogaine intoxication. Serial ECGs demonstrating delayed recovery of the corrected QT (QTc) interval due to long plasma half-life of the active metabolite noribogaine. Complete QTc normalization required 7 d. The absolute QT interval was measured using maximal slope technique that has been described previously. 7 The QTc interval was then calculated using Bazett's formula The present case extends our knowledge about the clinical manifestation of ibogaine-related cardiotoxicity. As previously reported, our patient presented with significant hypokalemia, which served as a proarrhythmic cotrigger and was related to the heavy gastrointestinal symptoms. 1 Those symptoms are predominantly caused by activation of central dopaminergic and serotonergic receptors. 3 The onset of symptoms in our case was consistent with the literature. Symptoms of cardiotoxicity can manifest within 1.5-76 hours postingestion. 1, 6 The massive QT prolongation up to 714 ms in our patient is among the highest reported so far. 1 The estimated ingested dose of 65-70 mg/kg would represent the highest survived ibogaine dose reported to date. However, this has to be interpreted with caution, as nonstandardized preparation of ibogaine capsules makes dose estimations challenging, and we did not perform a direct measure of the serum ibogaine concentration. Depending on the type of preparation, the total content of ibogaine alkaloid may vary from 15% to 50%. 6 It becomes obvious that those uncontrolled and nonstandardized preparations result in unpredictable dosing putting potential customers at risk.
The long half-life of the active metabolite noribogaine is well illustrated by the delayed QT recovery of our patient. As illustrated in Figure 2 , it took 7 days for our patient to normalize his corrected QT interval despite normal electrolytes and in the absence of any competing QT-affecting medication. None of the previous reports on ibogaine intoxication provided a detailed documentation of the QT recovery. Our findings illustrate the potential risk for late recurrence of ventricular arrhythmia and emphasize the need for prolonged cardiac monitoring in those patients.
In conclusion: Ibogaine intoxication is an uncommon, but potentially life-threatening scenario due to the high cardiotoxicity of this substance and urgent admission to a critical care unit is required.
Cardiotoxicity is characterized by massive QT prolongation with risk of ventricular arrhythmia that may develop early or late after ingestion. Delayed QT recovery is related to the long plasma half-life of the active metabolite and prolonged cardiac monitoring until entire QT normalization is recommended.
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